



Product Information

Roar LCAT Activity Assay Kit, 100 assays

Lecithin:Cholesterol Acyltransferase Activity Assay Kit
Catalog No. RB-LCAT


Assay Method:	Fluorometric
Number of Assays:	100 assays in 100 μ l total incubation volume
Kit Contents:	Substrate Reagent: 100 μ l Read Reagent: 30 ml Assay Buffer: 20 ml
Storage and Handling:	Store kit components at -20°C. If stored properly, components are stable for up to 1 year.
Instrumentation:	Fluorescence spectrophotometer: Excitation: 340 nm / Emission: 390 and 470 nm

Introduction

The plasma protein lecithin:cholesterol acyltransferase (LCAT) catalyzes the transfer of an acyl group from the sn2 position of phosphatidylcholine to the 3-hydroxyl group of cholesterol resulting in the formation cholesteryl ester. This enzymatic activity occurs on the surface of high density lipoprotein (HDL). The cholesteryl esters formed by LCAT may be packed into the core of HDL.

The **Roar RB-LCAT Activity Assay Kit** is a fluorometric assay useful for measuring phospholipase activity of LCAT. The assay may be validated by inhibition of LCAT with iodoacetate or another spectrally inert LCAT inhibitor. Please note that Ellman's reagent will quench fluorescence intensity.

Applications for this method include high-throughput screening, mechanism of action studies and structure-activity relationship (SAR) work. This assay, along with Roar's RB-LCFC assay, provides a complete set of tools for LCAT mechanism studies by detection of phospholipase and acyltransferase activity. Intra- and interassay coefficients of variation of the assay: <5% (Nakhjavani, 2011; Harangi, 2009; Kassai, 2007)



Overview of the Assay

The emission spectrum of the Substrate Reagent has two distinct peaks, 390 nm and 470 nm. The relative intensity of the peaks depend upon the concentration of hydrolyzed and intact substrate present in the assay. If the substrate is intact, the fluorophors are in close proximity and some energy of their excited state is dissipated by radiationless transitions. The emission intensity is predominately at the less energetic 470 nm peak. After hydrolysis of the substrate by LCAT, the fluorophors are not able to energetically interact and a shift in intensity is seen in the emission spectrum as an increase in 390 nm emission at the expense of the 470 nm emission peak. It is important to measure both 390 and 470 nm emission because this label is affected by many assay variables.

Method 1. Using a Bench-Top Fluorescence Spectrophotometer

1. Mix 1 μ l LCAT Substrate Reagent with 200 μ l Assay Buffer and LCAT source.
2. Incubate for 4 to 8 hours at 37 °C.
3. Add 100 μ l of the incubated mixture to 300 μ l of Read Reagent and then vortex. Read the fluorescent label at 340 nm excitation and emission at 390 nm and at 470 nm. NOTE: Do not incubate the assay with Read Reagent - it will inactivate LCAT.

Method 2. Microplate Method - We recommend U-bottom, black microplates (Thermo Scientific #7205 or VWR #25227-304).

1. Set up the assay in a polypropylene microplate with 0.5 μ l Substrate Reagent plus LCAT source in a total volume of 100 μ l with Assay Buffer. For example, use 4 μ l of normal human plasma.
2. Incubate for 2.5 hours at 37 °C.
3. Add 200 μ l of Read Reagent to the polypropylene plate and mix by aspiration/dispense with pipet.
4. Transfer 200 μ l of the mixture from the polypropylene plate to a black fluorescence compatible microplate and read the plate at 340 nm excitation, 390 nm and 470 nm emission.
5. Determine the ratio of 470/390 to compare plasma LCAT activity among patient samples.

Related Product

Roar LCFC-LCAT Activity Assay Kit (cat. #RB-LCFC), 100 assays:

For Research Use Only. Not for Diagnostic or Therapeutic Purposes.

RB-LCAT Cited References (2003-2013)

Roar LCAT Activity Assay Kit

1. Blesso CN, Andersen CJ, Barona J, Volek JS, Fernandez ML. Whole egg consumption improves lipoprotein profiles and insulin sensitivity to a greater extent than yolk-free egg substitute in individuals with metabolic syndrome. *Metabolism*. 2013;62(3):400-410.
2. McEneny J, Wade L, Young IS, et al. Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. *J Nutr Biochem*. 2013;24(1):163-168.
3. Wade L, Nadeem N, Young IS, et al. α -Tocopherol induces proatherogenic changes to HDL2 & HDL3: An in vitro and ex vivo investigation. *Atherosclerosis*. 2013;226(2):392-397. doi: 10.1016/j.atherosclerosis.2012.11.032.
4. Campbell SC, Moffatt RJ, Kushnick MR. Continuous and intermittent walking alters HDL2-C and LCATa. *Atherosclerosis*. 2011;218:524-529.
5. Masson D, Deckert V, Gautier T, et al. Worsening of diet-induced atherosclerosis in a new model of transgenic rabbit expressing the human plasma phospholipid transfer protein. *Arterioscler Thromb Vasc Biol*. 2011;31(4):766-774.
6. Nakhjavani M, Asgharani F, Khalilzadeh O, et al. Oxidized low-density lipoprotein is negatively correlated with lecithin-cholesterol acyltransferase activity in type 2 diabetes mellitus. *Am J Med Sci*. 2011;341(2):92.
7. Wang D, Han J, Yu Y, et al. Chitosan oligosaccharide decreases very-low-density lipoprotein triglyceride and increases high-density lipoprotein cholesterol in high-fat-diet-fed rats. *Exp Biol Med*. 2011;236(9):1064-1069.
8. Conklin DJ, Barski OA, Lesgards JF, et al. Acrolein consumption induces systemic dyslipidemia and lipoprotein modification. *Toxicol Appl Pharmacol*. 2010;243(1):1-12.
9. Wu X. Ground beef fatty acid composition alters HDL functionality. *FASEB J*. 2010;24(1_MeetingAbstracts):210.8.
10. Harangi M, Mirdamadi HZ, Seres I, et al. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. *Translational Research*. 2009;153:190-198. doi: 10.1016/j.trsl.2009.01.007.
11. Sheril A, Jeyakumar SM, Jayashree T, Giridharan NV, Vajreswari A. Impact of feeding polyunsaturated fatty acids on cholesterol metabolism of dyslipidemic obese rats of WNIN/GR-ob strain. *Atherosclerosis*. 2009;204(1):136-140.
12. Zerrad-Saadi A, Therond P, Chantepie S, et al. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein AI and HDL particle surface lipid rigidity. relevance to inflammation and atherogenesis. *Arterioscler Thromb Vasc Biol*. 2009;29:2169-2175.
13. Hersberger M, Rohrer L, von Eckardstein A. Lipoproteins. In: Blau N, Duran M, Gibson KM, eds. *Laboratory guide to the methods in biochemical genetics*. Springer; 2008:497-548. 10.1007/978-3-540-76698-8_25.
14. Jafarnejad A, Bathaie SZ, Nakhjavani M, Hassan MZ. Investigation of the mechanisms involved in the high-dose and long-term acetyl salicylic acid therapy of type I diabetic rats. *J Pharmacol Exp Ther*. 2008;324(2):850-857.
15. Jafarnejad A, Bathaie SZ, Nakhjavani M, Hassan MZ. Effect of spermine on lipid profile and HDL functionality in the streptozotocin-induced diabetic rat model. *Life Sci*. 2008;82(5-6):301-307.
16. Jafarnejad A, Bathaie SZ, Nakhjavani M, Hassan MZ, Banasadegh S. The improvement effect of L-lys as a chemical chaperone on STZ-induced diabetic rats, protein structure and function. *Diabetes Metab Res*. 2008;24(1):64-73. doi: 10.1002/dmrr.769.
17. Nakhjavani M, Esteghamati A, Esfahanian F, Ghanei A, Rashidi A, Hashemi S. HbA1c negatively correlates with LCAT activity in type 2 diabetes. *Diabetes Res Clin Pract*. 2008;81(1):38-41.
18. Pavlovic NM, Orem WH, Tatu CA, et al. The role of lecithin cholesterol acyltransferase and organic substances from coal in the etiology of balkan endemic nephropathy: A new hypothesis. *Food and Chemical Toxicology*. 2008;46:949-954.
19. Bajnok L, Seres I, Varga Z, et al. Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals. *Metabolism*. 2007;56(11):1542-1549.
20. Ghanei A, Esfahanian F, Esteghamati A, Behjati J, Hamidi S, Nakhjavani M. Lecithin cholesterol acyltransferase activity is decreased in type 2 diabetes mellitus. *Acta Med Iran*. 2007;45(6):481-486.
21. Kassai A, Illyes L, Mirdamadi HZ, et al. The effect of atorvastatin therapy on lecithin:Cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. *Clin Biochem*. 2007;40(1-2):1-5.
22. Kontush A, Therond P, Zerrad A, et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles. relevance to antiapoptotic and antioxidative activities. *Arterioscler Thromb Vasc Biol*. 2007;27:1843-1849.
23. Ng CJ, Bourquard N, Hama SY, et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol*. 2007;27(6):1368-1374.
24. Briand F, Magot T, Krempf M, Nguyen P, Ouguerram K. Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. *Eur J Clin Invest*. 2006;36(4):224-230.
25. Idzior-Walus B, Sieradzki J, Kostner G, et al. Familial lecithin-cholesterol acyltransferase deficiency: Biochemical characteristics and molecular analysis of a new LCAT mutation in a polish family. *Atherosclerosis*. 2006;185(2):413-420.
26. Kontush A, de Faria EC, Chantepie S, Chapman MJ. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. *Atherosclerosis*. 2005;182(2):277-285.
27. Nobecourt E, Jacqueminet S, Hansel B, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: Relationship to elevated oxidative stress and hyperglycaemia. *Diabetologia*. 2005;48(3):529-538.
28. Shearer GC, Newman JW, Hammock BD, Kaysen GA. Graded effects of proteinuria on HDL structure in nephrotic rats. *Journal of the American Society of Nephrology*. 2005;16(5):1309.
29. Su YR, Ishiguro H, Major AS, et al. Macrophage apolipoprotein A-I expression protects against atherosclerosis in ApoE-deficient mice and up-regulates ABC transporters. *Mol Ther*. 2003;8(4):576-583.
30. Wiltshire T, Pletcher MT, Batalov S, et al. Genome-wide single-nucleotide polymorphism analysis defines haplotype patterns in mouse. *Proceedings of the National Academy of Sciences*. 2003;100(6):3380-3385.

Roar Biomedical, Inc., Audubon Biomedical Center, 3960 Broadway, New York, NY 10032 USA
Tel: +1 (212) 280-2983 • Fax: +1 (212) 280-2968 • info@roarbiomedical.com • www.roarbiomedical.com

©1998-2013 Roar Biomedical, Inc. All rights reserved. This information is subject to change without notice.